STAT+: Sanofi research priorities in flux as new CEO logs in

STAT PlusNewsletterThe Readout Sanofi research priorities in flux as new CEO logs in A gene therapy for deafness, all eyes on Erasca, and other biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanApril 23, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. A gene therapy for deafness is starting to deliver real-world benefit. Also, ultra-cheap telehealth options are raising concerns about whether easier access to prescription drugs is coming at the expense of patient care. And, in front of Congress, RFK Jr. seems to be striking a different tune on vaccines.Advertisement Sanofi research priorities in flux as new CEO logs in From my colleague Andrew Joseph: One of the open questions about the future of Sanofi as Belén Garijo takes over as CEO this month is whether the company, which had upped its focus in immunology in recent years only to come up with lackluster results, will rebalance its priorities. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech April 24, 2026 STAT Plus: FDA to speed up review of three psychedelics as mental health treatments The Readout April 24, 2026 STAT Plus: Sanofi MS drug gets positive review in Europe following FDA Advertisement Biotech April 23, 2026 STAT Plus: Trump celebrates closing first round of drug pricing deals, promises more ahead D.C. Diagnosis April 23, 2026 STAT Plus: RFK Jr. backs off some MAHA issues Adam's Biotech Scorecard April 23, 2026 STAT Plus: Can Erasca be biotech’s next big thing? We’ll see Subscriber Picks